Chart, page-1859

Itsa,

I expect a little suprise ann relating to IP protection for other indications, that should give us another nudge.

Even though the larger inflammation market has been mentioned in presos ($104B), and the Diamond has mooted the possible application to Asthma, MS etc....there's been no real push tactically.

I expect this will change as soon as IP protection is locked in for other indications. The "data room" will be chockers with US big pharma looking for a P2 project.

ANP will keep DMD and will license out other indications ...that's my guess.

So $5 is a "rainbow" prediction as Akki would say, but i'm betting ANP would be taken out way before $5 valuation if ATL1102 is successful in Phase 2B.

I do like Gil's street cred and the more 'salesy' attitude.

Americans know how to sell....Gil and Goolsbee also know the Hedge Funds that bought up Sarepta back in the day.

So far, the science is working for us, things are looking good...

A lot of water to go under the bridge though.